Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study.

Jin, Kai-Qi; Liu, Xiao-Gang; Guo, Yan-Hua; Wu, Chun-Xiao; Dai, Jie; Li, Jia-Qi; Minervini, Fabrizio; Antonoff, Mara B; Friedlaender, Alex; Addeo, Alfredo; Kocher, Gregor; Grossi, Francesco; Zhu, Yu-Ming; Zhang, Peng; Jiang, Ge-Ning (2022). Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study. Translational lung cancer research, 11(9), pp. 1951-1960. AME Publishing 10.21037/tlcr-22-616

Preview

Text 68468-PB8-8121-R2.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (264kB) | Preview

Background

With the exception of very early-stage small cell lung cancer (SCLC), surgery is not typically recommended for this disease; however, incidental resection still occurs. After incidental resection, adjuvant salvage therapy is widely offered, but the evidence supporting its use is limited. This study aimed to explore proper adjuvant therapy for these incidentally resected SCLC cases.

Methods

Patients incidentally diagnosed with SCLC after surgery at the Shanghai Pulmonary Hospital in China from January 2005 to December 2014 were included in this study. The primary outcome was overall survival. Patients were classified into different group according to the type of adjuvant therapy they received and stratified by their pathological lymph node status. Patients' survival was analyzed using a Kaplan-Meier analysis and Cox regression analysis.

Results

A total of 161 patients were included in this study. Overall 5-year survival rate was 36.5%. For pathological N0 (pN0) cases (n=70), multivariable analysis revealed that adjuvant chemotherapy (ad-chemo) was associated with reduced risk of death [hazard ratio (HR): 0.373; 95% confidence interval (CI): 0.141-0.985, P=0.047] compared to omission of adjuvant therapy. For pathological N1 or N2 (pN1/2) cases (n=91), taking no adjuvant therapy cases as a reference, the multivariable analysis showed that ad-chemo was not associated with a lower risk of death (HR: 0.869; 95% CI: 0.459-1.645, P=0.666), while adjuvant chemo-radiotherapy (ad-CRT) was associated with a lower risk of death (HR: 0.279; 95% CI: 0.102-0.761, P=0.013).

Conclusions

Patients who incidentally receive surgical resection and are diagnosed with limited disease SCLC after resection should be offered adjuvant therapy as a salvage treatment. For incidentally resected pN0 cases, ad-chemo should be considered and for pN1/2 cases, ad-CRT should be received.

Interest & Impact

Downloads

13 since deposited on 19 Oct 2022
13 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item